Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 2056-2056 ◽  
Author(s):  
Michael Weller ◽  
Guido Reifenberger ◽  
Emilie Le Rhun ◽  
Jennifer Leigh Clarke ◽  
Riccardo Soffietti ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Dna Methyltransferase ◽  
Methylation Status ◽  
Related Factors ◽  
Immunological Parameters ◽  
Term Survival ◽  
Long Term Survival ◽  
Large Patient ◽  
The Us

2056 Background: Glioblastoma represents the most aggressive primary brain tumor in adults, and less than 5% of patients survive 5 years from diagnosis. Factors influencing this long-term survival are poorly understood. Methods: In cooperation with the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, more than 20 clinical sites in the US, Europe and Australia have registered patients with centrally confirmed glioblastoma who survived ≥ 5 years, collecting clinical data including therapy and quality of life-related factors, as well as biospecimens allowing to analyse molecular and immunological parameters. Results: At the cut-off of December 31, 2018, 392 patients were registered, of which 232 had glioblastoma confirmed by central pathology review; 59 dropped out due to histology other than glioblastoma. Glioblastomas were isocitrate dehydrogenase (IDH)-wildtype in 70.7% and had a positive O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status in 75.9%. Median age at diagnosis was 52 years (range: 21-77 years). There was enrichment for patients with gross total resection. Further analyses are ongoing. Conclusions: In a comprehensive effort, the consortium funded by the US Brain Tumor Funders’ Collaborative characterizes factors modulating long-term survival in glioblastoma in a unique large patient cohort. Clinical trial information: NCT 03770468.

scholarly journals ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi5-vi5
Author(s):  
Caroline Happold ◽  
Riccardo Soffietti ◽  
Christine Marosi ◽  
Jaap Reijneveld ◽  
Gabriele Schackert ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Molecular Genetic ◽  
Term Survival ◽  
Long Term Survival ◽  
The Brain

scholarly journals Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ying-Tso Chen ◽  
Shu-Shong Hsu ◽  
Chi-Man Yip ◽  
Ping-Hong Lai ◽  
Huai-Pao Lee
Keyword(s):  
Brain Tumor ◽  
Primitive Neuroectodermal Tumor ◽  
Case Reports ◽  
Primary Brain Tumor ◽  
Neuroectodermal Tumor ◽  
Disease Course ◽  
Term Survival ◽  
Long Term Survival ◽  
Genetic Features

Introduction. Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, is characterized by extensive heterogeneity in its clinicopathological presentation. A primary brain tumor with both astrocytic differentiation and neuronal immunophenotype features is rare. Here, we report a long-term survival patient who presented this rare form of GBM in the disease course. Presentation of Case. A 23-year-old woman, presenting with rapidly progressive headache and right-side weakness, was diagnosed with brain tumor over the left basal ganglion. She underwent the first craniectomy for tumor removal, and histopathology revealed classic GBM. Tumor recurrence occurred 8 years later. Another gross total resection was performed and pathology revealed GBM with the oligodendroglioma component (GBM-O). Due to disease progression, she received debulking surgery the following year. The third pathology revealed glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET). Discussion. GBM-PNETs are collision tumors with both neuronal and glial components. They are rare, and a few case reports have suggested that these tumors are associated with favorable outcomes but a higher risk of cerebrospinal fluid dissemination. Conclusion. We report a patient who developed the distinct pathologic variants of classic GBM, GBM-O, and GBM-PNET, throughout the disease course. Young age, aggressive surgical resection, and pathologic and genetic features may have contributed to the long-term survival of the patient.

scholarly journals P1.16-38 Racial Disparities in Long-Term Survival After Surgical Resection in the US

2019 ◽  
Vol 14 (10) ◽  
pp. S602
Author(s):  
M. Taylor ◽  
M. Smeltzer ◽  
N. Faris ◽  
M. Ray ◽  
C. Fehnel ◽  
...  
Keyword(s):  
Racial Disparities ◽  
Surgical Resection ◽  
Term Survival ◽  
Long Term Survival ◽  
The Us

Effect of seizure timing on long-term survival in patients with brain tumor

2021 ◽  
Vol 117 ◽  
pp. 107566
Author(s):  
Suyash Singh ◽  
Anant Mehrotra ◽  
Soumen Kanjilal ◽  
Vimal K. Paliwal
Keyword(s):  
Brain Tumor ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry

2017 ◽  
Vol 35 (11) ◽  
pp. 1162-1170 ◽  
Author(s):  
Wenhua Liang ◽  
Jiaxi He ◽  
Yaxing Shen ◽  
Jianfei Shen ◽  
Qihua He ◽  
...  
Keyword(s):  
Seer Database ◽  
Small Cell Lung ◽  
Term Survival ◽  
Node Negative ◽  
Long Term Survival ◽  
Cut Point ◽  
Resected Nsclc ◽  
N2 Disease ◽  
The Us

Purpose We investigated the correlation between the number of examined lymph nodes (ELNs) and correct staging and long-term survival in non–small-cell lung cancer (NSCLC) by using large databases and determined the minimal threshold for the ELN count. Methods Data from a Chinese multi-institutional registry and the US SEER database on stage I to IIIA resected NSCLC (2001 to 2008) were analyzed for the relationship between the ELN count and stage migration and overall survival (OS) by using multivariable models. The series of the mean positive LNs, odds ratios (ORs), and hazard ratios (HRs) were fitted with a LOWESS smoother, and the structural break points were determined by Chow test. The selected cut point was validated with the SEER 2009 cohort. Results Although the distribution of ELN count differed between the Chinese registry (n = 5,706) and the SEER database (n = 38,806; median, 15 versus seven, respectively), both cohorts exhibited significantly proportional increases from N0 to N1 and N2 disease (SEER OR, 1.038; China OR, 1.012; both P < .001) and serial improvements in OS (N0 disease: SEER HR, 0.986; China HR, 0.981; both P < .001; N1 and N2 disease: SEER HR, 0.989; China HR, 0.984; both P < .001) as the ELN count increased after controlling for confounders. Cut point analysis showed a threshold ELN count of 16 in patients with declared node-negative disease, which were examined in the derivation cohorts (SEER 2001 to 2008 HR, 0.830; China HR, 0.738) and validated in the SEER 2009 cohort (HR, 0.837). Conclusion A greater number of ELNs is associated with more-accurate node staging and better long-term survival of resected NSCLC. We recommend 16 ELNs as the cut point for evaluating the quality of LN examination or prognostic stratification postoperatively for patients with declared node-negative disease.

scholarly journals Long-term Survival in Stage IV Sigmoid Colon Cancer Initially Presenting as a Brain Tumor: Case Report

2011 ◽  
Vol 44 (1) ◽  
pp. 84-91
Author(s):  
Shintaro Nakajima ◽  
Katsuhito Suwa ◽  
Kazuo Kitagawa ◽  
Akihiko Fujita ◽  
Tetsuya Yamagata ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Brain Tumor ◽  
Case Report ◽  
Sigmoid Colon ◽  
Stage Iv ◽  
Sigmoid Colon Cancer ◽  
Term Survival ◽  
Long Term Survival

Long-term survival following colon cancer surgery: Variation associated with choice of anesthesia

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 17015-17015
Author(s):  
R. Christopherson ◽  
K. E. James ◽  
M. Tableman ◽  
P. Marshall ◽  
A. L. Kline ◽  
...  
Keyword(s):  
Colon Cancer ◽  
General Anesthesia ◽  
Cancer Patients ◽  
Tnm Staging ◽  
Immunological Parameters ◽  
Term Survival ◽  
Long Term Survival ◽  
Physiological Variables ◽  
Unexpected Findings

17015 Background: VA Cooperative Trial 345 randomized patients having abdominal surgery to unsupplemented general anesthesia (UGA) or epidural-supplemented general anesthesia (ESGA). The long-term clinical significance of the type of anesthesia for patients having surgery for colon cancer has not been well studied. We compared survival of patients with colon cancer randomized to ESGA to survival of those randomized to UGA. Methods: Survival of colon cancer patients was not a primary trial end point. We conducted a post hoc analysis of the colon cancer patients in the trial using TNM staging data from patient records. A Cox survival model was used to test the effects of pathological stage, type of anesthesia and other covariates on survival. Results: 177 patients were evaluable. In both trial arms, survival was similar (P = 0.23) until 4.56 years. After 4.56 years, patients assigned to UGA had significantly better survival (P = 0.01). In both trial arms, the survival in patients without metastases was similar initially, but those who received UGA had significantly better survival later. A similar statistically significant pattern was evident in patients with metastases. The long-term survival benefit of UGA was even more pronounced among patients with metastases and a diagnosis of alcoholism. Conclusions: This study provides the first evidence that ESGA may worsen long-term survival in colon cancer patients, especially those with metastases and alcoholism. Epidural anesthesia affects visceral blood flow, immunological parameters, post-operative pain and other physiological variables, which could explain these findings. Additional studies to confirm or refute these unexpected findings are warranted. No significant financial relationships to disclose.

scholarly journals ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi5-vi6
Author(s):  
Caroline Happold ◽  
Jörg Felsberg ◽  
Jennifer Clarke ◽  
Riccardo Soffietti ◽  
Christine Marosi ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Molecular Genetic ◽  
Term Survival ◽  
Long Term Survival ◽  
First Results ◽  
The Brain
Sign in / Sign up

Export Citation Format

Share Document